GSK LATAM
在场
GSK LATAM 的所有者是 GSK.
是其中之一......
- Forbes Global 2000 (#183);
- Fortune 500 Europe (#104);
- FTSE 350;
- Global Fortune 500 (#400);
- Stoxx 600;
- TOB Iconic 10,000.
GSK 是一家在股票代码 GSK (GB) 下上市的公司。
GSK 在 20 个国家有直接业务。GSK 拥有 23家子公司，其中包括 Aiolos Bio、GSK ANZ 和 GSK APAC。
他们在：
涉及GSK的并购和融资。
- GSK has announced the acquisition of Aiolos Bio (公布2024一月12号).
- GSK has announced the acquisition of Bellus Health (公布2023四月19号).
药店
GSK 拥有 1,840 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
- BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).
药店 行业的其他推荐联系人
消息
GSK LATAM 的最新新闻稿
- GSK highlights key data from hepatology portfolio at the AASLD’s The Liver Meeting® 2024, emphasising patient impact in areas of high unmet need | GSK
- GSK’s fully liquid Menveo meningococcal vaccine approved by European Commission | GSK
- Blenrep combinations accepted for review by the US FDA for the treatment of relapsed/refractory multiple myeloma | GSK
- Arexvy approval expanded to adults aged 50-59 at increased risk of severe RSV disease in Japan | GSK
- Linerixibat shows positive Phase III results in cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC) | GSK
- Statement: GSK continues to show strong leadership in its Access to Medicines Index ranking | GSK
- Blenrep shows overall survival benefit in head-to-head DREAMM-7 phase III trial for relapsed/refractory multiple myeloma | GSK
- New GSK-sponsored survey reveals unique gaps in care and support facing patients with gynaecologic cancers | GSK
- GSK on track to deliver 2024 outlooks with further good progress made in R&D | GSK
- GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline | GSK
- View more press releases Close
